BCI Remote Cable Recall Issued Due to Alarm Failure

|

Several lots of BCI alarm cables needed to activate life-saving alarms in hospital settings could fail, potentially posing a risk of severe injury or death for patients, federal health officials warn. 

The FDA issued a class 1 recall for BCI remote alarm cables this week after the manufacturer, Smiths Medical, became aware that the cables were not transferring alarms with some remote nurse alarm systems.

A class 1 recall is the most serious type of medical device recall, and is only issued when there is potential that the product in question may cause serious injury or may result in death. To date, there have been no reported cases of serious injury or death associated with the recalled BCI cables.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

BCI alarm cables are used in critical care situations to connect to remote nurse alarm systems used in ventilators, patient transport and anesthesia machines for pediatric and adult uses. The nurse alarm systems are used to notify healthcare workers in the event of serious adverse events or in cases of medical necessity, such as monitoring elevated pulse, high blood pressure and ventilator issues, among other problems.

The lot numbers of BCI alarm cables affected by the class 1 recall are W3398NO0820, WW3398NO0847, WW3398NO0948, WW3398NC0822, WW3398NC0847, and WW3398NC0947. They are designed to be used with 9004 Capnocheck Capnography systems to transfer alarm signals from Capnocheck Capnography systems to remote alarm system used for critical applications.

The recalled BCI cables were manufactured by Smiths Medical ADS in Saint Paul Minnesota and distributed to Colorado, Illinois, Indiana, Massachusetts, South Carolina and Wisconsin from October 2008 through Sept 2012.

Customer service agents from Smiths Medical originally issued an “urgent medical device field safety notice-recall” letter on February 6, notifying customers of the affected product, the problems with the cables, and actions customers should take.

They also instructed customers to inspect their inventory and remove the affected devices from use and to await contact from a customer representative with detailed instruction for returning products for replacement credit. Customers with questions can call (800) 258-5361.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.

Image Credit: |



1 Comments


Ellen
When My Mom was in KDMC in Ashland, KY. for 11 Days. The Alarms RARELY WORKED!!!!!

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera.
A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children.
Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.